Company news
SpectraCure AB news in 2025
SpectraCure AB's news releases, calls and decks from 2025, newest first.
Spectracure Q3 Net Loss SEK 35 Mln
November 13, 2025
Spectracure Says Study Shows Significant PSA Reduction In Prostate Cancer Patients
November 4, 2025
Spectracure Signs Agreement With Cheplapharm For Verteporfin Supply
October 21, 2025
Spectracure Q-Pro Patent Approved In Japan
October 13, 2025
Spectracure Gets Approval To Commence Clinical Trial
October 8, 2025
Spectracure Appoints Johannes Swartling As CEO
October 1, 2025
Spectracure Reports Positive Results In Prostate Cancer Study
September 22, 2025
SPEC: Clinical progress and new funding strengthen position despite ongoing losses
August 15, 2025
SPEC: Q1 2025 saw continued losses and a planned rights issue as SpectraCure advances clinical studies
May 28, 2025
SPEC: Net loss widened as SpectraCure advanced clinical trials, with new funding needed by mid-2025
February 20, 2025